ANRO Stock Summary and Trading Ideas (Alto Neuroscience | NYSE:ANRO)

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.

As of September 25, 2026, ANRO stock price declined to $26.49 with 343,899 million shares trading.

ANRO has a beta of 1.95, meaning it tends to be more sensitive to market movements. ANRO has a correlation of 0.05 to the broad based SPY ETF.

ANRO has a market cap of $1.04 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ANRO has outperformed the market in the last year with a return of +597.1%, while the SPY ETF gained +18.4%. However, in the most recent history, ANRO shares have underperformed the stock market with its stock returning +4.7% in the last 3 month period and -17.2% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.

ANRO support price is $26.08 and resistance is $28.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.